Search
for
Did you mean Cardiovascular Diseases?
Sort by
Research 30 of 1000+
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- Androgenetic alopecia as a cardiovascular risk factor
- 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
- Forensic approach in cases of anabolic-androgenic steroid abuse and cardiovascular mortality: insights from autopsy, histopathology, immunohistochemistry and toxicology
- Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in murine models of hormonal manipulation, ageing, and cardiac injury
- Androgens and Cardiovascular Disease
- Toxicity of repeated oral intake of organic selenium, inorganic selenium, and selenium nanoparticles: A review
- Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association?
- Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study
- Highlights
- Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- An in-depth review on the medicinal flora Rosmarinus officinalis (Lamiaceae).
- Association Between Fish Consumption and Risk of Cardiovascular Disease Mortality in Korean Men and Women: A Prospective Cohort Study
- Hutchinson-Gilford syndrome: History, causes, phenotype and research advances
- Executive Summary: Heart Disease and Stroke Statistics—2011 Update
- COMPARATIVE STUDY OF TROPONIN I LEVEL IN ALOPECIA AREATA, ANDROGENIC ALOPECIA AND HEALTHY CONTROL SUBJECTS
- Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome
- The treatment of polycystic ovary syndrome.
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Polycystic ovary syndrome
- Safety of Topical Minoxidil Solution: A One-Year, Prospective, Observational Study
- Cytostatics and immunosuppressive drugs
- Prostate cancer update: 2007
- Emergency preparedness in hair restoration surgery
- Men’s health in the United States: a national health paradox
- Female pattern hair loss, biological ageing and the Leiden Longevity study
- Reporting on Adverse Clinical Events
- Endoplasmic reticulum stress at the crossroads of progeria and atherosclerosis